These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 38898473)

  • 41. Caffeic acid phenethyl ester suppresses the expression of androgen receptor variant 7 via inhibition of CDK1 and AKT.
    Kuo YY; Huo C; Li CY; Chuu CP
    Cancer Gene Ther; 2024 Jun; 31(6):807-815. PubMed ID: 38480977
    [TBL] [Abstract][Full Text] [Related]  

  • 42. NF-κB2/p52:c-Myc:hnRNPA1 Pathway Regulates Expression of Androgen Receptor Splice Variants and Enzalutamide Sensitivity in Prostate Cancer.
    Nadiminty N; Tummala R; Liu C; Lou W; Evans CP; Gao AC
    Mol Cancer Ther; 2015 Aug; 14(8):1884-95. PubMed ID: 26056150
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Targeting the PI3K/AKT Pathway Overcomes Enzalutamide Resistance by Inhibiting Induction of the Glucocorticoid Receptor.
    Adelaiye-Ogala R; Gryder BE; Nguyen YTM; Alilin AN; Grayson AR; Bajwa W; Jansson KH; Beshiri ML; Agarwal S; Rodriguez-Nieves JA; Capaldo B; Kelly K; VanderWeele DJ
    Mol Cancer Ther; 2020 Jul; 19(7):1436-1447. PubMed ID: 32371590
    [TBL] [Abstract][Full Text] [Related]  

  • 44. TXNDC9 regulates oxidative stress-induced androgen receptor signaling to promote prostate cancer progression.
    Feng T; Zhao R; Sun F; Lu Q; Wang X; Hu J; Wang S; Gao L; Zhou Q; Xiong X; Dong X; Wang L; Han B
    Oncogene; 2020 Jan; 39(2):356-367. PubMed ID: 31477836
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Inhibition of the erythropoietin-producing receptor EPHB4 antagonizes androgen receptor overexpression and reduces enzalutamide resistance.
    Li C; Lanman NA; Kong Y; He D; Mao F; Farah E; Zhang Y; Liu J; Wang C; Wei Q; Liu X
    J Biol Chem; 2020 Apr; 295(16):5470-5483. PubMed ID: 32184358
    [TBL] [Abstract][Full Text] [Related]  

  • 46. TMPRSS2-ERG fusions confer efficacy of enzalutamide in an in vivo bone tumor growth model.
    Semaan L; Mander N; Cher ML; Chinni SR
    BMC Cancer; 2019 Oct; 19(1):972. PubMed ID: 31638934
    [TBL] [Abstract][Full Text] [Related]  

  • 47. PIAS1 is a determinant of poor survival and acts as a positive feedback regulator of AR signaling through enhanced AR stabilization in prostate cancer.
    Puhr M; Hoefer J; Eigentler A; Dietrich D; van Leenders G; Uhl B; Hoogland M; Handle F; Schlick B; Neuwirt H; Sailer V; Kristiansen G; Klocker H; Culig Z
    Oncogene; 2016 May; 35(18):2322-32. PubMed ID: 26257066
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Inhibition of androgen receptor transactivation function by adenovirus type 12 E1A undermines prostate cancer cell survival.
    Li D; Tian G; Wang J; Zhao LY; Co O; Underill ZC; Mymryk JS; Claessens F; Dehm SM; Daaka Y; Liao D
    Prostate; 2018 Nov; 78(15):1140-1156. PubMed ID: 30009471
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Proteostasis by STUB1/HSP70 complex controls sensitivity to androgen receptor targeted therapy in advanced prostate cancer.
    Liu C; Lou W; Yang JC; Liu L; Armstrong CM; Lombard AP; Zhao R; Noel ODV; Tepper CG; Chen HW; Dall'Era M; Evans CP; Gao AC
    Nat Commun; 2018 Nov; 9(1):4700. PubMed ID: 30446660
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Galectin-3 Is Implicated in Tumor Progression and Resistance to Anti-androgen Drug Through Regulation of Androgen Receptor Signaling in Prostate Cancer.
    Dondoo TO; Fukumori T; Daizumoto K; Fukawa T; Kohzuki M; Kowada M; Kusuhara Y; Mori H; Nakatsuji H; Takahashi M; Kanayama HO
    Anticancer Res; 2017 Jan; 37(1):125-134. PubMed ID: 28011482
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Targeting androgen receptor (AR) with antiandrogen Enzalutamide increases prostate cancer cell invasion yet decreases bladder cancer cell invasion via differentially altering the AR/circRNA-ARC1/miR-125b-2-3p or miR-4736/PPARγ/MMP-9 signals.
    Deng G; Wang R; Sun Y; Huang CP; Yeh S; You B; Feng C; Li G; Ma S; Chang C
    Cell Death Differ; 2021 Jul; 28(7):2145-2159. PubMed ID: 34127806
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Multimodal actions of the phytochemical sulforaphane suppress both AR and AR-V7 in 22Rv1 cells: Advocating a potent pharmaceutical combination against castration-resistant prostate cancer.
    Khurana N; Kim H; Chandra PK; Talwar S; Sharma P; Abdel-Mageed AB; Sikka SC; Mondal D
    Oncol Rep; 2017 Nov; 38(5):2774-2786. PubMed ID: 28901514
    [TBL] [Abstract][Full Text] [Related]  

  • 53. TALEN-engineered AR gene rearrangements reveal endocrine uncoupling of androgen receptor in prostate cancer.
    Nyquist MD; Li Y; Hwang TH; Manlove LS; Vessella RL; Silverstein KA; Voytas DF; Dehm SM
    Proc Natl Acad Sci U S A; 2013 Oct; 110(43):17492-7. PubMed ID: 24101480
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Melatonin Inhibits Androgen Receptor Splice Variant-7 (AR-V7)-Induced Nuclear Factor-Kappa B (NF-κB) Activation and NF-κB Activator-Induced AR-V7 Expression in Prostate Cancer Cells: Potential Implications for the Use of Melatonin in Castration-Resistant Prostate Cancer (CRPC) Therapy.
    Liu VWS; Yau WL; Tam CW; Yao KM; Shiu SYW
    Int J Mol Sci; 2017 May; 18(6):. PubMed ID: 28561752
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer.
    Hu R; Lu C; Mostaghel EA; Yegnasubramanian S; Gurel M; Tannahill C; Edwards J; Isaacs WB; Nelson PS; Bluemn E; Plymate SR; Luo J
    Cancer Res; 2012 Jul; 72(14):3457-62. PubMed ID: 22710436
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cellular androgen content influences enzalutamide agonism of F877L mutant androgen receptor.
    Coleman DJ; Van Hook K; King CJ; Schwartzman J; Lisac R; Urrutia J; Sehrawat A; Woodward J; Wang NJ; Gulati R; Thomas GV; Beer TM; Gleave M; Korkola JE; Gao L; Heiser LM; Alumkal JJ
    Oncotarget; 2016 Jun; 7(26):40690-40703. PubMed ID: 27276681
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Skp2 regulates androgen receptor through ubiquitin-mediated degradation independent of Akt/mTOR pathways in prostate cancer.
    Li B; Lu W; Yang Q; Yu X; Matusik RJ; Chen Z
    Prostate; 2014 Apr; 74(4):421-32. PubMed ID: 24347472
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Targeting GRP78-dependent AR-V7 protein degradation overcomes castration-resistance in prostate cancer therapy.
    Liao Y; Liu Y; Xia X; Shao Z; Huang C; He J; Jiang L; Tang D; Liu J; Huang H
    Theranostics; 2020; 10(8):3366-3381. PubMed ID: 32206096
    [No Abstract]   [Full Text] [Related]  

  • 59. Preclinical studies using cisplatin/carboplatin to restore the Enzalutamide sensitivity via degrading the androgen receptor splicing variant 7 (ARv7) to further suppress Enzalutamide resistant prostate cancer.
    Chou FJ; Lin C; Tian H; Lin W; You B; Lu J; Sahasrabudhe D; Huang CP; Yang V; Yeh S; Niu Y; Chang C
    Cell Death Dis; 2020 Nov; 11(11):942. PubMed ID: 33139720
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Silencing of PMEPA1 accelerates the growth of prostate cancer cells through AR, NEDD4 and PTEN.
    Li H; Mohamed AA; Sharad S; Umeda E; Song Y; Young D; Petrovics G; McLeod DG; Sesterhenn IA; Sreenath T; Dobi A; Srivastava S
    Oncotarget; 2015 Jun; 6(17):15137-49. PubMed ID: 25883222
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.